302 related articles for article (PubMed ID: 22738645)
1. Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization.
Roggers RA; Lin VS; Trewyn BG
Mol Pharm; 2012 Sep; 9(9):2770-7. PubMed ID: 22738645
[TBL] [Abstract][Full Text] [Related]
2. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP.
Zhao Y; Trewyn BG; Slowing II; Lin VS
J Am Chem Soc; 2009 Jun; 131(24):8398-400. PubMed ID: 19476380
[TBL] [Abstract][Full Text] [Related]
3. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
4. Lipid coated mesoporous silica nanoparticles as photosensitive drug carriers.
Yang Y; Song W; Wang A; Zhu P; Fei J; Li J
Phys Chem Chem Phys; 2010 May; 12(17):4418-22. PubMed ID: 20407714
[TBL] [Abstract][Full Text] [Related]
5. Lipid bilayer-coated mesoporous silica nanoparticles carrying bovine hemoglobin towards an erythrocyte mimic.
Tu J; Bussmann J; Du G; Gao Y; Bouwstra JA; Kros A
Int J Pharm; 2018 May; 543(1-2):169-178. PubMed ID: 29567198
[TBL] [Abstract][Full Text] [Related]
6. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
7. Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles.
Tsai CH; Vivero-Escoto JL; Slowing II; Fang IJ; Trewyn BG; Lin VS
Biomaterials; 2011 Sep; 32(26):6234-44. PubMed ID: 21684000
[TBL] [Abstract][Full Text] [Related]
8. Triggered release in lipid bilayer-capped mesoporous silica nanoparticles containing SPION using an alternating magnetic field.
Bringas E; Köysüren Ö; Quach DV; Mahmoudi M; Aznar E; Roehling JD; Marcos MD; Martínez-Máñez R; Stroeve P
Chem Commun (Camb); 2012 Jun; 48(45):5647-9. PubMed ID: 22543447
[TBL] [Abstract][Full Text] [Related]
9. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
10. Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery.
Gan Q; Dai D; Yuan Y; Qian J; Sha S; Shi J; Liu C
Biomed Microdevices; 2012 Apr; 14(2):259-70. PubMed ID: 22124885
[TBL] [Abstract][Full Text] [Related]
11. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
[TBL] [Abstract][Full Text] [Related]
13. PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect.
Lin J; Cai Q; Tang Y; Xu Y; Wang Q; Li T; Xu H; Wang S; Fan K; Liu Z; Jin Y; Lin D
Int J Pharm; 2018 Jan; 536(1):272-282. PubMed ID: 29079221
[TBL] [Abstract][Full Text] [Related]
14. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
15. A magnetic, reversible pH-responsive nanogated ensemble based on Fe3O4 nanoparticles-capped mesoporous silica.
Gan Q; Lu X; Yuan Y; Qian J; Zhou H; Lu X; Shi J; Liu C
Biomaterials; 2011 Mar; 32(7):1932-42. PubMed ID: 21131045
[TBL] [Abstract][Full Text] [Related]
16. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
17. Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA.
Li Z; Zhang Y; Zhang K; Wu Z; Feng N
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):578-587. PubMed ID: 29374971
[TBL] [Abstract][Full Text] [Related]
18. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells.
Slowing I; Trewyn BG; Lin VS
J Am Chem Soc; 2006 Nov; 128(46):14792-3. PubMed ID: 17105274
[TBL] [Abstract][Full Text] [Related]
19. pH and thermo dual-stimuli-responsive drug carrier based on mesoporous silica nanoparticles encapsulated in a copolymer-lipid bilayer.
Wu X; Wang Z; Zhu D; Zong S; Yang L; Zhong Y; Cui Y
ACS Appl Mater Interfaces; 2013 Nov; 5(21):10895-903. PubMed ID: 24127854
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
